Highlights Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
45.88 ^USD	+3.36%		+7.57%	+106.02%

Jun. 16	Transcript : Agios Pharmaceuticals, Inc. - Special Call
Jun. 15	Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress	Jun. 15	CI
Agios Says of Trial of Blood Disorder Drug Mitapivat Met Primary Endpoint; Shares Rise	Jun. 03	MT
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study	Jun. 03	RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia	Jun. 03	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	May. 28	MT
Agios Pharmaceuticals, Inc. Announces $905 Million Purchase Agreement for Vorasidenib Royalty	May. 28	CI
Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	May. 02	MT
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M	May. 02	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	Feb. 15	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	Jan. 08	CI
Agios' blood disorder drug meets goals of late-stage study	Jan. 03	RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	Jan. 03	CI
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition	Dec. 09	CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes	Nov. 20	CI
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $7.5M	Nov. 02	MT
Agios Pharmaceuticals Signs License Deal With Alnylam for Potential Treatment for Rare Blood Disease	23-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Highlights

Filters